Skip to content

Funding Announcements

Filter

Filter & sort

Keyword

Tag

Round

Sort by

Clear

The latest funding rounds from the UK tech ecosystem. Updated 5 November 2026.

Announcements

6,266

Total raised

£165B

disclosed amounts

This month

£202M

raised so far

Other
$4.0M

The London-based NatureTech startup secured $4m to scale its platform and deploy new artificial intelligence tools for nature recovery.

"As threats to the natural world become more urgent, any organisation dependent on land – whether directly or through their supply chain – has a business resilience need to invest in nature recovery."
— Rafi Cohen, Co-CEO
Series C
£8.9M

The financing extension brings Nuclera's total Series C funding to $87m and will advance antibody engineering capabilities.

"Since our initial investment, Nuclera has made meaningful progress in expanding the capabilities, adoption, and global reach of the eProtein Discovery platform. The extension of the system into full-format antibody expression, purification, and binding validation represents a significant step forward, particularly as biologics discovery becomes increasingly driven by AI-enabled workflows that require scalable, high-quality datasets. Elevage is proud to continue supporting Nuclera as it evolves into a foundational platform for protein and antibody engineering, helping researchers accelerate discovery timelines and reduce friction across the drug development process."
— Michael Wasserman, Chief Operating Officer
Pre-Seed
£2.2M

The pre-series A round was backed by The FSE Group through the South West Investment Fund.

"Difficulty taking tablets is a common problem in paediatrics but extends to adults experiencing swallow impairment, including those suffering from serious conditions such as stroke, dementia and some forms of cancer. Our liquid products are effective and stable at room temperature with a long shelf life, improving medication adherence, dosage accuracy and convenience for the NHS, patients, and caregivers. We are thrilled to receive this investment, which will help us make a significant impact on the global pharmaceutical landscape."
— Richard Reavley, Group CEO